Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
|Articles|January 28, 2021
How to Keep Health Care Workers Safe While Administering the COVID-19 Vaccine
Pharmacy Times interviewed Rob LaHayne, CEO of TouchCare, on how pharmacies and other health care setting can keep their employees and patients safe as they administer the COVID-19 vaccine.
Advertisement
Pharmacy Times® interviewed Rob LaHayne, the CEO of TouchCare, on how pharmacies and other health care setting can keep their employees and patients safe as they administer the coronavirus disease 2019 (COVID-19) vaccine.
For the full conversion, see the video above.
Advertisement
Related to this article
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
4
FDA Approves Insulin Efsitora, Once-Weekly Basal Insulin Injection for Adults With T2D
5